Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD

This study has been completed.

Study NCT00634413 Information provided by Pulmagen Therapeutics

First Received on March 6, 2008. Last Updated on February 27, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Additional conditions recognized in this trial

Inflammation
Lung Diseases
Lung Diseases, Obstructive
Pneumonia
Pulmonary Disease, Chronic Obstructive
Respiration Disorders

More general conditions related to this trial

Pathologic Processes
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions listed in this trial

Theophylline - ADC4022
Placebo
Budesonide

Additional drug interventions recognized in this trial

Theophylline

Sponsors listed in this trial

Pulmagen Therapeutics

Back to top of Main Content